Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) -Part 2 on Triage, Treatment and Follow-up
I Guideline Information
The Oncology Guidelines Program of the Association of Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V., AWMF), the German Cancer Society (Deutsche Krebsgesellschaft e. V., DKG) and German Cancer Aid (Deutsche Krebshilfe, DKH).
Guidelines Program of the DGGG, the OEGGG and the SGGG. For more information on the Guidelines Program, please refer to the end of this article.
Recommendations The second part of this short summary deals with the triage, treatment and follow-up care of cervical dysplasia. With regard to those women who do not participate in screening, the guideline authors recommend sending out repeat invitation letters or an HPV self-collection kit. Colposcopy should be carried out for further investigation if cytology findings are Pap II-p and HPV test results are positive or if the results of an HPV 16 or HPV 18 screening test are positive. A single abnormal Pap smear should be triaged and investigated using HPV testing or p16/Ki67 dual staining. 
Guideline authors
The German Society of Gynecology and Obstetrics (DGGG, mandate holder: Prof. Dr. Peter Hillemanns, Hanover) was the lead medical society responsible for the compilation of this guideline. The guideline is issued by the Oncological Guidelines Program. Every participating medical society nominated a mandate holder, with the board of the respective society confirming the mandate in writing. ▶ Table 1 lists the medical societies and other organizations which participated in developing the guideline together with their respective mandated representatives. Only mandate holders nominated by participating societies and organizations were eligible to take part in the voting process (consensus process) after they had disclosed and excluded any conflicts of interest. A patient representative was directly involved in the compila-▶ Table 1 Participating professional societies and other organizations.
Participating professional societies and other organizations
Mandate holder tion of this guideline. Ms. Marion Gebhardt (Frauenselbsthilfe nach Krebs e. V. [Self-help for Women after Cancer]) was involved in developing the guideline right from the start, attended the consensus conferences and had the right to vote in the consensus conferences.
II Guideline Application
Purpose and objectives
The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer. The S3 guideline provides important information and support for the planned organized screening for cervical cancer in Germany.
The old German-language S2k guideline "Prevention, Diagnosis and Therapy of HPV Infections and Preinvasive Lesions of the Female Genitalia" was consulted, and the new guideline focused on those aspects which deal with the cervix. Guideline recommendations on primary prevention were taken from the updated German-language S3 guideline "082/002 Vaccination to Prevent HPV-associated Neoplasias" and supplemented with additional information about the impact of HPV vaccination on screening. The German-language S3 guideline "032/033OL Cervical Cancer: Diagnosis, Treatment and Follow-up" published in 2014 covers all aspects of invasive cervical cancer.
Targeted areas of patient care
This S3 guideline on the prevention of cervical cancer presents various aspects of the prevention of cervical cancer and the diagnosis, treatment and follow-up of cervical cancer including highgrade preinvasive lesions. The main priorities of the guideline were analyzing existing data in order to optimize screening strategies for cervical cancer by determining the optimal test procedures, organizations, investigative algorithms and treatments, and considering how best to encourage women who previously refused to attend screening to participate in the program. In addition, the guideline considered the impact of HPV vaccination on screening strategies for cervical cancer.
Target patient group
This S3 guideline is aimed at all women aged 20 and above.
Target user groups/target audience
The recommendations of the guideline are addressed to all physicians and professionals involved in screening for cervical cancer, particularly gynecologists, pathologists and cytologists as well as all healthcare professionals working in dysplasia outpatient clinics and centers.
Other target groups include: ▪ scientific medical societies and professional associations which are involved in screening for cervical cancer, ▪ womenʼs advocacy groups (womenʼs health organizations, patient and self-help organizations), ▪ quality assurance organizations and similar projects on national and federal state levels, ▪ healthcare policy institutions and decision-makers at national and federal state levels, ▪ payers, ▪ the general public to inform them about what constitutes good medical practice.
Adoption and period of validity
This guideline is valid from 31 December 2017 through to 31 December 2020. Because of the contents of the guideline, this period of validity is only an estimate. The guideline may need to be updated if new scientific evidence appears or the methodology used in the guideline is developed further. Moreover, the key statements and recommendations of the guideline should be subjected to regular editorial checks, and the contents of the guideline should be regularly reviewed.
III Methodology

Basic principles
The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidencebased subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches. This guideline is classified as: S3.
Grading of evidence
The GRADE (GRADE = Grading of Recommendations Assessment, Development and Evaluation) system developed by the GRADE Working Group [1] (www.gradeworkinggroup.org) was used to evaluate the quality of evidence of the studies identified and used for this guideline (▶ Table 2 ).
▶ Table 2 Grading of the quality of evidence based on the GRADE system.
GRADE Beschreibung Symbol
High quality "We are very confident that the true effect lies close to that of the estimate of the effect."
⊕⊕⊕⊕
Moderate quality
"We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different."
⊕⊕⊕⊖
Low quality
"Our confidence in the effect estimate is limited:
The true effect may be substantially different from the estimate of the effect."
⊕⊕⊖⊖
Very low quality
"We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect."
⊕⊖⊖⊖
Grading of recommendations
The methodology of the Oncology Guidelines Program requires guideline authors to assign a level of recommendation to each recommendation which indicates the strength of the recommendation. The strength of each recommendation is agreed upon in a formal consensus process which requires structured consensus conferences [2] . (Details are available in the German-language Guideline Report.) As part of this process, the mandate holders with voting rights formally voted on the recommendations in this guideline. This guideline includes information on the grading of the evidence of the underlying studies used for all evidence-based Statements and Recommendations and additionally shows the strength of each recommendation (level of recommendation). In accordance with the AWMF Guidance Manual [2] , this guideline differentiates between three strengths or levels of recommendation, and the respective level of recommendation is reflected by the syntax used in the recommendation (▶ Table 3 ).
The decision criteria used to determine the level of recommendation are explained in the German-language Guideline Report for this guideline.
Statements
Statements are expositions or explanations of specific facts, circumstances, or problems, with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on study results or expert opinions (▶ Table 4 ).
Expert consensus (EC)
Statements/Recommendations which were issued based on the expert consensus of the guideline authors are identified as being based on expert consensus. No symbols or letters are used to grade the level of expert consensus; the respective level of consensus is demonstrated by the syntax used (must/should/may) in accordance with the differentiation described in ▶ Table 3 .
IV Guideline
1 Differential diagnosis and evaluation algorithm 1.1 Indication for coloscopy depends on probability of CIN 3
1.2
What is the best diagnostic work-up strategy to investigate abnormal cytology
Atypical squamous or glandular cells (Pap II-p, II-g)
▶ Table 3 Level of recommendation. 
Level of recommendation
14.5.
If CIN 1 is confirmed histologically, the initial approach must be to wait and see and re-evaluate the patient after 6 months*.
EC 14.6. If CIN 1 is accompanied by Pap smear results classified as group IVa or higher and the lesion cannot be adequately evaluated and extends into the endocervix, the endocervical canal must be evaluated by histopathology.
EC * Colposcopy with a positive predictive value for CIN 2 or CIN 3 of at least 65 % is recommended if the patient is managed with expectant monitoring or undergoes purely ablative treatment [130] .
No. Recommendations/Statements GRADE Sources
14.7.
If a histologically confirmed CIN 2 lesion can be evaluated in its entirety and the transitional area between squamous and columnar epithelium can be entirely visualized, the initial approach is to wait and see and re-examine the patient after 6 months*.
EC 14.8. If the transitional area between squamous and columnar epithelium cannot be entirely visualized in a patient with a histologically confirmed CIN 2 lesion and/or at least one Pap smear was classified as IVa, the endocervical canal must be evaluated by histopathology.
No. Recommendations/Statements GRADE Sources
14.9.
A lesion confirmed histopathologically as CIN 3 must be resected. EC
5.3.4
Treatment recommendations for adolescents 5.3.5 Excision procedures vs. hysterectomy for cervical adenocarcinoma in situ (ACIS) 5.3.6 R0 resection and approach for R1 resection 6 P r e g n a n c y
No. Recommendations/Statements GRADE Sources
14.10.
A conservative strategy must be used for women up to the age of 24 with histopathologically confirmed CIN 2 and can be used for women up to the age of 24 with histopathologically confirmed CIN 3, provided ▪ the lesion can be evaluated colposcopically in its entirety, and ▪ it does not contain any atypical glandular components, and ▪ an invasive process can be excluded with a high degree of certainty.
Treatment should be carried out if the CIN 2 persists for more than 24 months or the CIN 3 persists for more than 12 months or the lesion expands into the endocervix.
Treatment must be tissue-sparing.* EC 14.11. Women up to the age of 24 with CIN 3 who are managed conservatively should be monitored by a certified dysplasia clinic (s. Chapter 2 Colposcopy).
No. Recommendations/Statements GRADE Sources
14.12.
The definitive histopathological diagnosis of ACIS (with the differential diagnosis excluding invasive adenocarcinoma) must be obtained by excision.
Hysterectomy should be the definitive treatment for ACIS if the patient plans to have no more children.
If the patient wishes to have children, R0 resection must be carried out and the patient must be followed up using colposcopy, cytology and HPV testing.
EC
No. Recommendations/Statements GRADE Sources
14.13. The goal must be to achieve R0 resection of a CIN 3. EC
14.14.
If the resection status after surgical excision of a CIN 3 is R1 and there is no suspicion of invasive cancer, the patient must attend a follow-up appointment after 6 months with cytology and HPV testing.
If the findings at follow-up show that CIN 3 has persisted, the patient must be re-operated. 
EC
17.3.
It is not possible to make any recommendations about complementary medical treatments because of the lack of meaningful studies.
EC
No. Recommendations/Statements GRADE Sources
18.1. Information given to the women who participate in screening for cervical cancer must cover the following aspects:
▪ an explanation of the disease, ▪ the natural progression of infection with HPV and associated cell changes, ▪ the different HPV types, ▪ the risk factors for cervical cancer, ▪ the impact on the patientʼs partner(s), ▪ a description of the screening method, ▪ information about the benefits and harm of screening methods, ▪ information on the quality of the screening methods.
EC
No. Recommendations/Statements GRADE Sources
18.2. The information given to women with findings at screening which require further investigation must include the following:
▪ the findings ▪ the differential diagnosis ▪ the treatment options ▪ the treatment goals ▪ the duration of the different treatments and how they are carried out ▪ the necessity of regular follow-up appointments EC In Germany, HPV-based screening carried out at intervals of every 3-5 years is considered to be cost-effective. HPV-based screening carried out at intervals of every 2 years has a less favorable cost-effectiveness ratio. Annual screening significantly increases costs without generating a significant additional benefit.
⊕⊖⊖⊖ [158] [ 
